EC Approves Genmab's TEPKINLY for Relapsed/Refractory Follicular Lymphoma, First Bispecific Option
GMAB sits 39% above its 52-week low of $20.225.
Summary
The European Commission has approved Genmab's TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. This marks the first and only bispecific-based therapy approved in Europe for this indication, offering a chemotherapy-free option. The approval is based on strong Phase 3 data, showing a 79% reduction in disease progression or death and a 74% complete response rate. This significantly expands the market opportunity for TEPKINLY and reinforces its potential as a core therapy across B-cell malignancies, building on recent positive trial results for the drug in other lymphoma types.
At the time of this announcement, GMAB was trading at $28.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17B. The 52-week trading range was $20.23 to $35.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.